FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL											
OMB Number:	3235-0287										
Estimated average b	urden										

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Goeltz II Robert C.</u>						2. Issuer Name and Ticker or Trading Symbol Unity Biotechnology, Inc. [UBX]								eck all applic Directo	able) r			Owner
(Last) (First) (Middle) C/O UNITY BIOTECHNOLOGY, INC. 3280 BAYSHORE BOULEVARD				06	3. Date of Earliest Transaction (Month/Day/Year) 06/20/2019								A below)	or (give title Other (spec or) below) Chief Financial Officer				
(Street) BRISBANE CA 94005					- 4. -	4. If Amendment, Date of Original Filed (Month/Day/Year)							Lin	Individual or Joint/Group Filing (Check Applicable te) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S	tate)	(Zip)															
		Та	ble I - Nor	n-Deriv	vativ	re Se	ecurities	Acc	quired,	Dis	posed o	f, or Be	neficial	y Owned				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				····		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction D Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			5) Securitie Beneficia	5. Amount of Securities Beneficially Owned Following		: Direct I r Indirect I str. 4) (7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) (D)	Price	Transact (Instr. 3 a	ion(s)			msu. 4)
Common Stock 06/20/					0/201	/2019		A		21,075 ⁽¹⁾ A		\$0.0	124,404 ⁽²⁾			D		
			Table II - I				urities <i>i</i> ls, warra							Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable ar Expiration Date (Month/Day/Year)		•	7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securitie Beneficia Owned Following Reported	e s ally	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				С	Code	v	(A)		Date Exercisal:		Expiration Date	Title	Amount or Number of Shares		Transacti (Instr. 4)	лі(S)		
Stock Option (Right to Buy)	\$9	06/20/2019			A		116,850		(3)	(06/19/2029	Common Stock	116,850	\$0.00	116,85	50	D	

Explanation of Responses:

- 1. RSUs which vest 1/3 annually over 3 years measured from June 20, 2019.
- 2. Includes 1,981 shares acquired under the Issuer's Employee Stock Purchase Plan on May 15, 2019.
- 3. The shares subject to the option vest and become exercisable in 48 successive, equal monthly installments measured from June 20, 2019, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.

/s/ Tamara L. Tompkins,

Attorney-in-Fact for Robert C. 06/24/2019

Goeltz II

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.